论文部分内容阅读
目的:探讨n 18F-脱氧葡萄糖(FDG) PET/CT不同代谢参数与晚期肺腺癌化疗有效性的关系及其预后价值。n 方法:筛选2017年8月至2019年6月于海南省肿瘤医院行治疗前n 18F-FDG PET/CT检查、获得明确病理结果并接受了规范化化疗的晚期肺腺癌患者进行回顾性分析。共127例[男70例、女57例，年龄(56.8±10.1)岁]入选，收集患者临床特征，测量PET/CT不同代谢参数，随访患者无进展生存期(PFS)。采用受试者工作特征(ROC)曲线、Kaplan-Meier法单因素分析以及Cox风险比例回归模型分析各因素对生存的影响。n 结果:所有PET/CT代谢参数中，最大标准摄取值(SUVn max)、30%肿瘤代谢体积(MTVn 30)及30%病灶糖酵解总量(TLGn 30)曲线下面积较大，分别为0.581、0.606和0.693，最佳截断值分别为10.12、20.21 cmn 3和81.25 g。Kaplan-Meier法单因素分析及Cox回归分析显示，临床分期[风险比(n HR)＝0.293(95% n CI：0.190~0.451)，n P20.21 cmn 3是接受化疗的晚期肺腺癌患者PFS差的独立预后因素[n HR＝0.738 (95% n CI：0.611~0.893)，n P＝0.002)；n HR＝1.502(95% n CI：1.037~2.177)，n P＝0.032]。n 结论:临床分期、吸烟状态及MTVn 30是接受化疗的晚期肺腺癌患者PFS的独立预后因素。MTVn 30≤20.21 cmn 3有望成为晚期肺腺癌患者的影像预后标志物，并帮助筛选经化疗有生存获益的患者。n “,”Objective:To explore the clinical significance of different metabolic parameters measured by n 18F-fluorodeoxyglucose (FDG) PET/CT in predicting the effectiveness of chemotherapy in advanced lung adenocarcinoma patients.n Methods:A set of metabolic parameters of PET/CT and clinical characteristics which were detected from 127 patients (70 males, 57 females, age (56.8±10.1) years) with advanced lung adenocarcinoma treated with at least two cycles of chemotherapy in Hainan Cancer Hospital between August 2017 and June 2019 were retrospectively analyzed. The effects of those parameters on patients′ survival were analyzed by receiver operating characteristic (ROC) curve, Kaplan-Meier method (log-rank test) and Cox proportional hazards model.Results:Maximum standardized uptake value (SUVn max), metabolic tumor volume 30% (MTVn 30), and total lesion glycolysis 30% (TLGn 30) had larger areas under the curve (0.581, 0.606 and 0.693 respectively) compared with other imaging parameters, and the optimal cut-off values were 10.12, 20.21 cmn 3 and 81.25 g respectively. Kaplan-Meier univariate and Cox analyses synergistically showed that clinical stage (hazard ratio (n HR)=0.293(95% n CI: 0.190-0.451), n P20.21 cmn 3 were independent prognostic factors for poor PFS in patients with advanced lung adenocarcinoma receiving chemotherapy (n HR=0.738(95% n CI: 0.611-0.893), n P=0.002; n HR=1.502(95% n CI: 1.037-2.177), n P=0.032).n Conclusions:Clinical stage, smoking and MTVn 30 are independent prognostic factors of PFS in patients with advanced lung adenocarcinoma receiving chemotherapy. MTVn 30≤20.21 cmn 3 is expected to be an image biomarker for predicting survival and selecting patients with advanced lung adenocarcinoma who are more likely to benefit from chemotherapy.n